• 主题
高级搜索  >
历史搜索 清空历史
您现在的位置：首页> 中文期刊>其他>心血管创新与应用

心血管创新与应用

心血管创新与应用

CVIA杂志由胡大一教授在2014年长城国际心脏病学会议（GW-ICC）期间提议创办，邀请前ACC主席C. Richard Conti教授担任主编。CVIA是GW-ICC官方期刊，前任主席马长生教授和现任主席张健教授为CVIA杂志副主编。完全开放获取（OA）期刊，严格执行同行评议，内容涉及心血管疾病的所有领域，重实用和创新，多为客座主编专题约稿形式。采用ScholarOne投稿处理系统。目前已正式出版心力衰竭、电生理、介入、预防性心脏病学等10期专刊。
更多
  • 发文量：233
  • 被引量：3
  • H指数：0
  • 开始收录时间：2015,0(0)
  • CNKI综合因子：0.0
  • 维普期刊影响因子： 0.08
  • 万方期刊影响因子：0.0
  • 创刊时间：2015
  • 国内刊号/CN：-
    国际刊号/ISSN：2009-8618
  • 发行周期：季刊
    邮发代号：-
  • 主管单位：-
    主办单位：长城国际心脏病学会议
心血管创新与应用-联系信息
  • 主编：C.Richard Conti;Jianzeng Dong
  • 电话：010-64456372
  • 邮箱：jz_dong@126.com
  • 地址：Beijing Anzhen Hospital, Capital Medical University No 2. Anzhen Road, Chaoyang District, Beijing
  • 邮编：100029
心血管创新与应用-获奖情况
  • 暂无获奖信息
  • 收录汇总
  • 刊内文献检索
  • 投稿信息

刊期浏览

心血管创新与应用 >2023年第1期

学科

年度

全选（0）
排序：
共4384条结果
  • 摘要：Sarcoidosis is a rare condition of granulomatous infi ltration of many tissues of the body,including the heart.Cardiac sarcoidosis has been challenging to study,as it is often asymptomatic,although the initial presentation can be sudden cardiac death.The incidence and prevalence rates have been diffi cult to establish and no expert agreed upon guidelines for diagnosis and management of cardiac sarcoidosis exist,and clinical manifestations are varied.The pathophysiology of granuloma formation in the myocardium as well as other tissues is governed by immune response to some environmental antigen.Genetics is also thought to play a role,although gene alterations have not been extensively studied,and no specifi c set of genetic mutations has been identifi ed to aid in identifi cation of individuals at risk of developing disease.Epigenetic factors likely play a signifi cant role in modulation of gene expression with respect to immune response.There is no standardized screening tool for the identifi cation of cardiac sarcoidosis.The presence of systemic sarcoidosis and new-onset third-degree heart block or ventricular arrhythmias warrants further investigation for cardiac sarcoidosis.MRI and PET are useful in helping to identify cardiac sarcoidosis but are not stand-alone tests.Endomyocardial biopsy is the gold standard but has a low yield owing to the patchy nature of granuloma formation in the myocardium.Therapy should be instituted early and involves immunosuppressive therapy with predominant use of corticosteroids.Arrhythmias,either ventricular or high-grade heart blocks,are managed with device therapy.Clinical presentation may warrant use of antiarrhythmic agents and/or catheter ablation.Survival and disease prognosis are dependent on early diagnosis and treatment.This review details the current understanding of cardiac sarcoidosis and highlights diagnostic strategies and treatment with the aim of guiding the clinician to early identifi cation of patients and implementation of appropriate management in this rare disease entity.
  • 摘要：Despite the development of noninvasive tools as echocardiography,right-sided heart catheterization remains an integral part of the cardiovascular evaluation.In the last decade,better understanding of the hemodynamic process before heart failure decompensation led to improvement of outpatient strategies to prevent it.Advances in implantable wireless technology now allow frequent and direct measurement of intracardiac fi lling pressures,which can be monitored by health care providers to help tailor therapy to reduce fi lling pressures and hospital readmission rates.
  • 摘要：Critical cardiogenic shock remains a problem with staggering mortality,with the best hope of survival depending on timely and aggressive intervention.This often requires the use of extracorporeal mechanical support in addition to vasoactive medications to manage patients through their initial insult.The decision to use such support must be made early in the clinical presentation,and is best done in a multidisciplinary fashion.In this article,we review the literature and provide an algorithm for the treatment of cardiogenic shock.
  • 摘要：Heart failure is the most common cause of hospitalization in the United States.Just as the prevalence of heart failure has increased,the number of diseases identifi ed that result in the heart failure syndrome has escalated.Certain cardiomyopathies that have previously been regarded as very rare are being recognized with increasing frequency,because of improved imaging techniques and an increased understanding of the pathophysiologic mechanisms that result in these diseases.Improved echocardiographic techniques and methods such as spectral Doppler and 3D image rendering,along with the use of advanced diagnostic tools such as cardiac CT angiography and cardiac magnetic resonance imaging are now common.These advanced imaging methods have led to an increased appreciation of the frequency of diseases such as isolated left ventricular noncompaction and cardiac amyloidosis.Left ventricular noncompaction,once thought to occur in roughly one in one million patients,may actually be seen in fewer than one in 1000 patients.Cardiac amyloidosis,in the senile form,may exist in 80% of 80-year-old patients,although the incidence of clinical symptoms is less.As the genetic alterations that contribute to these diseases are further elucidated,improved diagnosis and a better understanding of the prognosis of these uncommon cardiomyopathies will follow.
  • 摘要：Heart failure(HF)is a complex clinical syndrome that results from any structural or functional impairment of ventricular fi lling or ejection of blood.HF is one of the most important and severe end stages of many cardiovascular diseases.Epidemiological studies of HF have focused mainly on the prevalence,incidence,mortality,fatality,and distribution and temporal trends of these indicators among different populations.This review highlights important epidemiological studies of HF in China.
  • 摘要：Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fi ll with or eject blood.The echocardiogram is the single most performed and useful study in these patients.This article reviews the role of the echocardiogram in the evaluation of the heart failure patient,without focusing on the left ventricle.The discussion includes the use of the echocardiogram in the assessment of the right ventricle and diastolic function and in detecting hemodynamic and morphologic changes in heart failure over a period of time.In addition,we highlight some of the limitations of echocardiography in the assessment of these patients.
  • 摘要：When China opened its doors to the world 26 years ago,there were very few cardiology meetings organized in China with an international outlook.Shortly thereafter,in 1990,the Great Wall International Congress of Cardiology(GW-ICC)held its inaugural meeting.In its fi rst few years,the main focus of the GW-ICC was promoting research and education within the Chinese cardiology community,and on promulgating techniques such as catheter ablation of tachyarrhythmias and balloon angioplasty.Even from this early stage,the GW-ICC became a great social and scientifi c success.The reason for this success was that the GW-ICC offered opportunities for Chinese cardiologists to make direct contact with their US and European colleagues who in turn loved to come to China and learn about the issues facing cardiologists here.
  • 摘要：Right ventricular failure(RVF)remains the primary cause of death in patients with pulmonary arterial hypertension.We review the pathophysiology of RVF,including the remodeling and ventriculoarterial uncoupling that occurs when the failing right side of the heart is unable to compensate for a rising afterload.Secondly,the noninvasive imaging techniques used in the assessment of RVF are explored,including echocardiography,cardiac magnetic resonance imaging,computed tomography,and positron emission tomography.Third,we describe how these imaging techniques and a patient’s clinical characteristics may be used to determine prognosis.Lastly,we explore the medical and surgical/interventional treatment options for RVF.Despite these treatment options,morbidity and mortality remain high in this patient population.The discovery of new prognostic indicators,use of hybrid imaging for early detection of RVF,and strategies to prevent the development of RVF will be important if outcomes in this patient population are to improve.
  • 摘要：Standard Therapy for Heart Failure Until now the principal focus of heart failure therapy has been on the sympathetic nervous system and the renin-angiotensin system.Beta blockade counters the unwanted effects of catecholamines on the myocardium as well as moderately reducing afterload.Since angiotensin is a vasoconstrictor and has some toxic effect on the myocardium,both contributing to heart failure,inhibition of the renin–angiotensin system has been logical therapy for heart failure.However,use of angiotensinconverting enzyme(ACE)inhibitors may increase bradykinin levels,which are responsible for the cough that may be associated with their use as well as angioedema that may result from the same medications.
  • 摘要：Over 20 years of research has led to the now widely accepted role of cardiac resynchronization therapy(CRT)in medically refractory,mild to severe systolic heart failure(HF)with increased QRS duration.In addition to conferring a mortality benefi t,CRT has been shown to reduce HF hospitalization rates and improve functional status in this population.However,not all patients consistently demonstrate a positive response to CRT.Efforts to improve response to CRT have focused on improving patient selection and optimizing device implantation and follow-up,thereby correcting electrical and mechanical dyssynchrony.In this article we review the pathobiology of cardiac dyssynchrony,the rationale for the use of CRT,the history and the state of the art of CRT,and guidelines and recommendations for CRT,while also focusing on the areas of controversy and potential future applications.
  • 摘要：Introduction:Congestive heart failure(CHF)accounts for over$32 billion in health care costs per year and is at the epicenter of health care reform.CHF remains a major cause of hospitalizations.It is known and has been reported that missed diagnosis of and missed opportunities to treat heart failure are associated with higher mortality and morbidity.CHF disease management programs have emerged as a potential solution to the CHF epidemic.The paradox remains that CHF disease management programs still cluster in tertiary hospital systems.The impact of heart failure specialists and specialty teams in community health systems is less well understood.Currently there are not enough CHF-trained teams in the community setting to address this unmet health need.Methods:We explored the impact of CHF clinics in a community-based hospital system on readmission rates,mortality,and symptomatic relief.A total of 384 patients were enrolled in the clinic between 2012 and 2015.Data collected included age,sex,type of heart failure,New York Heart Association class,ejection fraction,serum creatinine and brain natriuretic peptide values,and readmission and mortality rates within 30 days,3 months,6 months,and 1 year.We also compared readmission rates between patients who were followed up in the CHF clinic versus those who were not seen in the CHF clinic.Results:A statistically signifi cant difference was demonstrated in readmission rates between patients who were followed up in the CHF clinic versus those who did not visit the CHF clinic for up to 1 year of follow-up.Conclusion:CHF community hospital clinics that use a rapid and frequent follow-up format with CHF-trained teams effectively reduce rehospitalization rates up to 1 year.
  • 摘要：It is estimated that more than one million heart failure hospitalizations occur each year.Systolic heart failure and heart failure with preserved ejection fraction contribute equally to heart failure hospitalizations.Heart failure readmission rates continue to be about 25%.Strategies to reduce heart failure readmission are key to reducing hospitalization rates.The strategies to reduce heart failure hospitalization are as follows:(1)During hospitalization,diuresis to the euvolemic state is essential.Fifty percent of discharged heart failure patients have minimal weight loss during the hospitalization,representing minimal diuresis,but still fl uid overload.(2)During hospitalization,interrogate the defi brillator or biventricular pacemaker(if applicable)to ensure that there is no right ventricular pacing and there is appropriate biventricular pacing.Interrogation of devices can identify arrhythmia or suboptimal biventricular pacing,which can contribute to decompensation.(3)Before discharge,identify the reason for decompensation,such as atrial fibrillation,infection,pulmonary embolism,or noncompliance.(4)Before discharge a multidisciplinary team is needed to educate the patient on diet,medications,fl uid weight surveillance,and exercise.(5)A postdischarge visit should occur within 10 days and with emphasis on uptitration of neurohormonal blockers and continued congestion management.Such interventions conducted by a multidisciplinary team have the potential to reduce heart failure hospitalization rates.
  • 摘要：Despite widespread awareness and use of scientifi cally proven life-prolonging medical and device-based therapies over the last two decades,heart failure remains a leading cause of morbidity,mortality,and health care expenditure in the United States.Mechanical circulatory support with a continuous-fl ow left ventricular assist device(CF-LVAD),either as a bridge to heart transplantation or as destination therapy,is an increasingly used treatment modality for patients with advanced heart failure syndromes that worsen despite their receiving standard therapies.CF-LVAD support creates unique hemodynamic alterations that must be understood to provide appropriate care for these patients before and after implantation.Echocardiography is essential in the evaluation of patients who are being considered for or are mechanically supported by CF-LVADs.Here we provide a focused clinical review on the use of echocardiography in two main aspects of the evaluation of these patients:(a)optimal patient selection for CF-LVAD support and(b)followup assessment of optimal pump function.
  • 摘要：Introduction,Naccarelli et al.review the field of stroke prevention in atrial fi brillation and emphasizes the point that a large number of patients are not anticoagulated[1].In numerous trials,NOACS have been shown to be better than Warfarin in reducing intra cranial hemorrhage and hemorrhagic stroke in patients with non-valve atrial fibrilation[2].But it is important to point out that the absolute risk reduction is small.As far as I can tell,no trial has compared NOACS to placebo.Whereas warfarin has been compared to placebo and has been shown to be markedly effective as an anticoagulant to prevent stroke.
  • 摘要：Cardiovascular disease(CVD)and depression and anxiety contribute substantially to the current disease burden worldwide as well as in China.Both depression and anxiety are highly prevalent among patients with CVD.We systematically reviewed the literature to disentangle the role of depression and anxiety disorders in the onset and prognosis of CVD with an emphasis on cohort studies conducted in the Chinese population.Despite the lack of large-scale prospective studies in China,the available evidence implies that both depression and anxiety are closely associated with the onset and prognosis of CVD,including ischemic heart disease and stroke,in Chinese adults.Putative behavioral and biological mechanisms are implicated in the link between depression/anxiety and CVD.Timely screening and diagnosis followed by proper treatment should be implemented for depression and anxiety in both the general population and patients with CVD.Current standard treatments such as selective serotonin reuptake inhibitors and psychotherapies are recommended for CVD patients with depression,although their efficacy for reducing CVD morbidity and mortality remains uncertain.In conclusion,prospective studies on the link between depression/anxiety and the onset and prognosis of CVD are urgently needed in the Chinese population,and more efforts are warranted to examine the efficacy of depression and anxiety treatments for CVD patients,particularly the integrated care model of including psychiatrists in a multidisciplinary clinical group.
  • 摘要：If systolic anterior motion(SAM)of a redundant anterior leaflet of the mitral valve is combined with systolic thickening of an asymmetric septum,(ASH),a narrow outflow channel of the left ventricle is formed.This narrowed outflow channel is then responsible for the mid systolic pressure difference between the body of the left ventricle and the out flow area of the left ventricle.This results in hypertrophic“obstructive”cardiomyopathy(HOCM).
  • 摘要：Inherited cardiomyopathies are major causes of morbidity and mortality and include a group of cardiac disorders such as hypertrophic cardiomyopathy(HCM),dilated cardiomyopathy,arrhythmogenic right ventricular dysplasia/cardiomyopathy(ARVD/C),left ventricular noncompaction(LVNC),and restrictive cardiomyopathy(RCM).These diseases have a substantial genetic component and predispose to sudden cardiac death.Since the first gene was identified as a disease-causing gene for HCM over two decades ago,more than eighty genes have been identified to be associated with inherited cardiomyopathies and genetic testing has become prevalent in making clinical diagnosis.With the advent of next-generation sequencing technology,genetic panel testing of inherited cardiomyopathies has become feasible and cost efficient.In this review,we summarize the individual cardiomyopathies with the emphasis on cardiomyopathy genetics and genetic testing.
  • 摘要：Background:The safety and efficacy of coronary artery bypass grafting(CABG)and second-generation drug-eluting stents(DESs)in patients with coronary artery disease(CAD)remain controversial.Therefore we aimed to compare the outcomes of CAD patients treated with CABG and second-generation DESs.Methods:We systematically searched the PubMed,Cochrane Library,Ovid,and Elsevier databases.Studies comparing second-generation DESs with CABG in CAD patients were included.RevMan 5.3 was used to extract and pool the data from the applicable studies.Results:Six trials(N=6604 participants)were included in this meta-analysis.Among all of the CAD patients,second-generation DESs were associated with no differences in the risks of all-cause death[risk ratio(RR)1.18,95% confi dence interval(CI)0.98–1.43,P=0.09],cardiovascular death(RR 1.14,95% CI 0.81–1.59,P=0.45),myocardial infarction(RR 1.22,95% CI 0.98–1.54,P=0.08),and stroke(RR 0.83,95% CI 0.59–1.17,P=0.29),but increased the risks of revascularization(RR 1.95,95% CI 1.66–2.30,P<0.001)and major adverse cardiac and cerebrovascular events(RR 1.72,95% CI:1.31–2.26,P<0.001)when compared with CABG.Conclusions:In the treatment of CAD patients,second-generation DESs was not associated with increased risks of all-cause death,cardiovascular death,myocardial infarction,and stroke,but increased the risks of revascularization and major adverse cardiac and cerebrovascular events when compared with CABG.
  • 摘要：Some have suggested the term“Precision”medicine replace“Personalized”medicine.I don’t like either term and I’ll tell you why.What is Precision?The word Precision can be defi ned simply as reproducibility and does not necessarily mean that the diagnosis is accurate.Thus,if the medical decision is precise but not necessarily accurate it is not very useful.Accuracy is defined as being near to the true or desired value.e.g.consider a target on a rifl e range;if the shots have a tight grouping anywhere on the target,they are precise but they are only precise and accurate if that tight grouping is in the Bull’s eye.
  • 摘要：Aim:To investigate the effect of home-based cardiac rehabilitation on functional capacity,health behavior,and risk factors in patients with acute coronary syndrome in China.Methods:Eighty patients with acute coronary syndrome were enrolled in this prospective randomized controlled study.Patients in the cardiac rehabilitation group(n=52)received home-based cardiac rehabilitation with a heart manual and a home exercise video for 3 months and patients in the control group(n=28)received only routine secondary prevention.The 6-min walk distance,laboratory test results,healthy behavior(questionnaire),quality of life(12-item Short Form Health Survey),anxiety(7-item Generalized Anxiety Disorder Questionnaire),and depression(9-item Patient Health Questionnaire)were evaluated at the beginning and after treatment for 3 months.Results:Compared with baseline data,52 patients who participated in cardiac rehabilitation had longer 6-min walk distance(515.26±113.74 m vs 0.445.30±97.92 m,P<0.0002),higher proportions of“always exercise”(78.26% vs.28%,P<0.05),“always limit food with sugar”(65.22% vs 12%,P<0.05),“always eat fruits 200–400 g every day”(82.61% vs.4%,P<0.05).and“always eat vegetables 300–500 g every day”(21.74%vs.12%,P<0.06)after treatment for 3 months.The low-density lipoprotein cholesterol control rate(52.17% vs.28%,P<0.05)and the systolic blood pressure control rate(100%vs.68%,P<0.05)were also signifi cantly increased after treatment for 3 months in the cardiac rehabilitation group.No signifi cant increase was found in the control group after treatment for 3 months.No cardiac-event related to home exercise was reported in both groups.Conclusion:Home-based cardiac rehabilitation is a feasible and available cardiac rehabilitation mode in China.
  • 摘要：In 2003,I was invited to attend and present a scientific paper at the GWICC meeting in Beijing,China,by Professor Hu Dayi.At the time Prof Hu was chief of cardiology in Beijing and Dean of a medical school in Shanghai.This conference was and still is the largest cardiology educational and scientific program in China and is attended by more than ten thousand persons,mostly Chinese,but also Europeans,Americans,and other nationalities.
  • 摘要：Since President Obama announced the Precision Medicine Initiative in the United States,more and more attention has been paid to precision medicine.However,clinicians have already used it to treat conditions such as cancer.Many cardiovascular diseases have a familial presentation,and genetic variants are associated with the prevention,diagnosis,and treatment of cardiovascular diseases,which are the basis for providing precise care to patients with cardiovascular diseases.Large-scale cohorts and multiomics are critical components of precision medicine.Here we summarize the application of precision medicine to cardiovascular diseases based on cohort and omic studies,and hope to elicit discussion about future health care.
  • 摘要：Background:The hospitalization burden of congenital heart disease(CHD)at the national or regional level in China remains unknown.We aimed to evaluate the recent patient characteristics and temporal trends of hospitalizations for CHD in Beijing.Methods:Patients hospitalized for CHD in Beijing from 2007 to 2011 were identified from the Hospital Discharge Information System.Patient characteristics were recorded,and trends in hospitalization rates were analyzed by Poisson regression after adjustment for age and sex.Results:A total of 53,064 patients were admitted for CHD in Beijing during the study period,among whom 50.5% were children younger than 5 years,30.0% were adults,18.5% had severe CHD,86.9% were nonpermanent Beijing residents,and 81.3% were admitted to cardiac-specific tertiary hospitals.The hospitalization rate increased from 10.2 per 100,000 population in 2007 to 12.4 per 100,000 population in 2011,representing a signifi cant increase after adjustment for age and sex(P=0.009).However,the trends varied in different groups.The rates halved in 2011 for both nonsevere CHD and severe CHD compared with the rates in 2010,whereas increasing trends were noticed in children aged 1–4 years and adults for nonsevere CHD across the study period.Conclusions:The overall rate of CHD hospitalization has been increasing in Beijing,whereas not all patient groups have the same trend.The hospitalization rate decreased among infants,while the rate for nonsevere CHD increased signifi cantly among adults.These findings will be of importance for future allocation of health resources.
  • 摘要：Amlodipine/valsartan(Aml/Val)single-pill combination(SPC)therapy has been widely used and studied in clinical practice in recent years.This article reviews the Chinese and English literature on the clinical use of Aml/Val SPC therapy in Chinese hypertensive patients.According to five studies concerning the efficacy and safety of this treatment,Aml/Val SPC therapy was more efficacious than monotherapy with valsartan,amlodipine,or the nifedipine gastrointestinal therapeutic system.This treatment showed greater blood pressure-lowering effects,a higher blood pressure control rate,and a higher response rate.Aml/Val SPC treatment was well tolerated,with adverse event rates similar to those of monotherapy with valsartan or amlodipine and significantly rarer adverse events compared with the nifedipine gastrointestinal therapeutic system.Aml/Val SPC is a highly efficacious and well-tolerated antihypertensive treatment in Chinese hypertensive patients.
  • 摘要：Cardiovascular diseases(CVD)have become the main cause of death and a critical public health burden in contemporary China.I was invited by Dr.Richard Conti,editor in chief of the journal as the guest editor of this issue focusing on CVD in China.It is my privilege to work with the leading cardiologists and research scientists in the field to delineate the outline of CVD in China,including epidemiology,prevention,rehabilitation,clinical management et al.This issue not only elaborates the major clinical issues but also highlights future perspectives in cardiovascular disease of China.
  • 摘要：The objective of this review was to assess the use of heart failure biomarkers in China.The literature of the commonlyused and new heart failure biomarkers had been reviewed in China.It is concluded that not only to consider the use of the new markers,but to study the combination use of the markers and/or other indexes would be the next step for a future heart failure study.Also,individualized and combinational use of the heart failure markers might be the most fitting to adapt to the developmental changes in China.
  • 摘要：Atrial fibrillation(AF)is the commonest cardiac arrhythmia,with significant morbidity and mortality.More than half of patients with AF are still symptomatic despite adequate anticoagulation and rate control.If antiarrhythmic drugs are ineffective or poorly tolerated,AF patients are then typically treated with catheter ablation to restore sinus rhythm.In the past 20 years,AF ablation has developed from a specialized,experimental procedure into a common treatment in the cardiovascular field.Various ablation techniques and mapping technologies have been described and are continuing to evolve for increased safety and efficacy.An incomplete list of such techniques and technologies would include focal and segmental,circumferential and linear,complex fractionated atrial electrogram,ganglionated plexus,focal impulse and rotor modulation,body surface potential mapping–guided,real-time MRI–guided,cryoballoon,visually guided laser balloon,radiofrequency hot balloon,contact force sensing catheter,multielectrode catheter,and hybrid ablations.This review examines the history of invasive AF treatment and its evolution into catheter ablation but mainly focuses on the discussion of various ablation techniques and technologies leading to our current understanding of the ablation therapy of this most common arrhythmia.
  • 摘要：Objective:The randomized controlled trial(ClinicalTrials.gov identifier NCT02990741)will investigate whether more frequent electrocardiographic(ECG)recordings and analyses with an automated ECG system would improve detection of atrial fibrillation compared with a single annual ECG screen in elderly Chinese in community health centers.Design:Men and women(≥65 years)will be randomized into intensive(n=3500)and usual(n=3500)screening groups,and within the intensive screening group into intensive screening(n=2625)and more intensive screening(n=875)subgroups.ECG recordings will be performed with an automated ECG analysis system(AliveCor heart monitor)at 1 year in the usual screening group,at 3,6,9,and 12 months in the intensive screening subgroup,and at 1,2,3,and 4 weeks and 3,6,9,and 12 months in the more intensive screening subgroup.The primary outcome is the detection rate of atrial fibrillation between the usual screening group and the intensive screening group.Sample size estimation was based on a projected detection rate of atrial fibrillation of 2.0% by a single ECG recording at 12 months,an improvement of 50% with more frequent ECG recordings,α=0.05,power of 80%,and a one-sided test.Conclusions:The trial will provide evidence on the clinical effectiveness of more frequent ECG recordings by a handheld automated analysis system in the detection of atrial fibrillation.
  • 摘要：The 2016 revision of the“Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults”is the outcome of the joint efforts of the members of an expert panel for more than 1 year,and is based on the 2007 guidelines.There is no doubt that the release of the 2007 guidelines greatly facilitated the management of dyslipidemia and the prevention and treatment of atherosclerotic cardiovascular diseases(ASCVDs)in China.However,an update of the guidelines for the management of dyslipidemia in Chinese adults is urgently needed since huge changes have occurred in the concepts of dyslipidemia research and control during the last decade.
  • 摘要：Advanced age brings a higher incidence of thrombosis-related diseases.Although antithrombotic therapy significantly reduces the risk of ischemic events,relatively higher bleeding rates result in increased mortality and worse prognosis in the elderly.Thus the benefits and harms of antithrombotic drugs should to be carefully evaluated.In this review,we summarize current evidence and updated guidelines regarding antithrombotic therapy in the aging population.

    心血管创新与应用的期刊信息

    • 创刊时间：2015
    • 地区：CN
    • 语言：中文
    • 热门主题：CARDIOVASCULAR CORONARY HEART DISEASE CARDIOLOGY VENTRICULAR CARDIAC HEART_FAILURE ARTERY ATRIAL
    • 学科分类：

    心血管创新与应用的获奖情况

    心血管创新与应用的收录情况

    • • 开放获取期刊指南
    • • 医学文摘
    • • 哥白尼索引
    • • 生物医学检索系统

    心血管创新与应用的投稿信息

    • 通讯地址：Beijing Anzhen Hospital, Capital Medical University No 2. Anzhen Road, Chaoyang District, Beijing
    • 邮编：100029
    • 联系电话：010-64456372
    • 邮箱：jz_dong@126.com
    免费订阅本刊

    客服邮箱：kefu@zhangqiaokeyan.com

    京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有 出版物经营许可证

    • 客服微信

    • 服务号